APOE and Stroke: Treatment with GSK’547 was limited to 20 weeks WD because the survival rate of ApoE−/− Fbn1C1039G+/− mice can drop below 50% after 20–25 weeks on WD due to myocardial infarction and stroke [28,40], and because 20 weeks WD was reported to suffice to induce an advanced plaque phenotype in ApoE−/− Fbn1C1039G+/− mice [27,28].